On the suitability of Innovar, a neuroleptic analgesic, for cardiovascular experiments

Abstract

The effects of 0.2 and 0.5 mL/kg Innovar (a neuroleptic analgesic) on cardiovascular functions and reflexes in rabbits were measured. We recorded the effects of Innovar on arterial pressure, heart rate, respiration rate, ventricular contractility, and arterial oxygen tension, as well as the drug's effects on the bradycardia and vasoconstrictor response to cigarette smoke stimulation of the nose (the so-called "nasopharyngeal reflex").In animals given 0.2 mL/kg Innovar, all steady state cardiovascular variables had returned to pre-Innovar levels in 45 min, as had the efficacy of the nasopharyngeal reflex. In animals given 0.5 mL/kg Innovar, all steady state cardiovascular variables, except [Formula: see text] were slightly but significantly depressed for up to 135 min after injection. The nasopharyngeal reflex returned to normal within 90 min.Because of the calmative and analgesic effects of Innovar, and its only moderate effects on cardiovascular functions and reflexes, we feel it is a suitable neuroleptic analgesic agent for cardiovascular experiments where neither fully conscious nor surgically anesthetized animals can be used.